NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

January 18, 2006 10:00 ET

E. Coli Contamination a World-Wide Public Health Threat; Nymox NXC-4720 Product in Development for E. Coli O157:H7 Contamination

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Jan 18, 2006) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has under development a new proprietary treatment of E. coli O157:H7, a potentially deadly form of a common bacteria that has proven to be a major public health threat to food and water supplies world-wide. In December, 18 children in Oregon became ill from drinking contaminated milk. Other recent outbreaks of deadly E. coli O157:H7 contamination have occurred in Wales, Ireland, France, Canada and the United States from a variety of sources, including ground beef, lettuce, bean sprouts, milk, water supplies and petting zoos. In the U.S. alone, E. coli O157 contamination causes an estimated 73,480 illnesses a year, with young children being particularly at risk for developing highly serious medical complications, and has led in the recall of over a million pounds of frozen ground beef in 2005.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has developed NXC-4720, a new proprietary treatment of potentially fatal E. coli O157:H7 contamination. Laboratory studies showed that NXC-4720 is capable of reducing the level of E. coli O157 contamination on fresh beef by over 99%.

E. coli O157:H7 infection can cause severe bloody diarrhea and abdominal cramps, leading in some cases to kidney failure, particularly in young children and in the elderly, with often serious long term and sometimes fatal results.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com